Weiss Multi-Strategy Advisers’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,000	Closed	-$928K	–	583
2014 Q4	$928K	Sell	10,000 -5,000	-33%	-$395K	0.03%	291
2014 Q3	$1.03M	Buy	15,000 +11,309	+306%	+$810K	0.03%	373
2014 Q2	$387K	Buy	3,691 +851	+30%	+$72.4K	0.01%	563
2014 Q1	$236K	Buy	+2,840	New	+$263K	﹤0.01%	879

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Weiss Multi-Strategy Advisers's GEVA Position: Q1 2015 in Review

Weiss Multi-Strategy Advisers sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 10,000 shares — an estimated $928K sold.

Weiss Multi-Strategy Advisers first reported a position in GEVA in Q1 2014 and held it in 4 quarters. The position peaked at $1.03M in Q3 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Weiss Multi-Strategy Advisers reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 10,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $928K.
Weiss Multi-Strategy Advisers first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 4 quarters.
Weiss Multi-Strategy Advisers's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.03M in Q3 2014.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2015, filed 15 May 2015.